Vivacitas Oncology is a company developing approaches for cancers resistant to standard treatment modalities. It operates two platforms: a development platform aiming to advance second- and third-generation camptothecins (Rubitecan/Orathecin and AR-67) in various cancers, and a platform focused on improving chemotherapeutic drugs.